Get the Stockscreener App
13.44
0.37%
-0.05
Ars Pharmaceuticals Inc stock is traded at $13.44, with a volume of 1.04M.
It is down -0.37% in the last 24 hours and up +0.75% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$13.49
Open:
$13.45
24h Volume:
1.04M
Relative Volume:
0.67
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-28.60
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-7.05%
1M Performance:
+0.75%
6M Performance:
-21.13%
1Y Performance:
+52.73%
1-Day Range:
$13.36
$14.00
1-Week Range:
$13.06
$14.35
52-Week Range:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.44 | 1.42B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharma’s epinephrine nasal spray 1mg now available in US - Yahoo
Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg - GlobeNewswire
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - Stock Titan
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Medical Professionals Reference
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership - simplywall.st
(SPRY) Investment Analysis - news.stocktradersdaily.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals Partners with ALK for Neffy Promotion - Investing.com Australia
ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US - marketscreener.com
ARS Pharma in pact with ALK-Abelló for neffy (SPRY:NASDAQ) - Seeking Alpha
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S - marketscreener.com
ALK-Abello (AKBLF) Partners with ARS Pharma for Needle-Free Alle - GuruFocus
ALK enters into neffy® co-promotion agreement in the USA - The Manila Times
ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season - Nasdaq
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ... - Eagle-Tribune
ARS Pharma Partners With ALK to Expand neffy Nasal Spray to 9,000 US Pediatricians | SPRY Stock News - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
ARS Pharmaceuticals Has A Blockbuster Candidate (NASDAQ:SPRY) - Seeking Alpha
(SPRY) On The My Stocks Page - news.stocktradersdaily.com
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia
US High Growth Tech Stocks To Watch Now - Yahoo Finance
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
10 Unstoppable Stocks That Could Double Your Money - Insider Monkey
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Raymond James maintains Strong Buy on SPRY stock, $32 target - Investing.com
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):